Trials / Unknown
UnknownNCT04054531
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
An Open-label, Phase II Study of KN046 Evaluating the Efficacy and Safety of KN046 Plus Platinum-based Doublet Chemotherapy as First Line Therapy in Advanced Non-small Cell Lung Cancer Subjects.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II study of KN046 plus platinum-based doublet chemotherapy in previously untreated advanced non-squamous and squamous NSCLC subjects. The study will assess primarily the safety and efficacy of KN046 plus platinum-based doublet chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | KN046 | IV infusion |
| DRUG | Paclitaxel | IV infusion |
| DRUG | Pemetrexed | IV infusion |
| DRUG | Carboplatin | IV infusion |
Timeline
- Start date
- 2019-09-04
- Primary completion
- 2021-03-01
- Completion
- 2021-06-01
- First posted
- 2019-08-13
- Last updated
- 2019-09-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04054531. Inclusion in this directory is not an endorsement.